RATIO OF INNATE AND ADAPTIVE IMMUNITY CELLS IN PERIPHERAL BLOOD DEPENDING ON HISTOGENESIS AND DEGREE OF ANAPLASIA OF BRAIN TUMORS
Keywords:
glioma, meningioma, pituitary adenoma, peripheral blood, platelets, neutrophils, lymphocytes.Abstract
Summary. Aim: to investigate the composition and ratio of innate and adaptive immunity cells in peripheral blood in patients with brain tumors of different histogenesis and histostructure. Object and methods: the indicators of peripherical blood parameters were studied
in 105 patients with neuroectodermal (n = 67), mesenchymal (n = 20), neuroepithelial (n = 18) brain tumors
and 28 patients with chronic non-oncological diseases
of the central nervous system. Determination of peripheral blood parameters was carried out on the automatic
hematological analyzer MINDRAY BC-3000 plus. The
absolute content of platelets (PLT), neutrophils (NPH)
and lymphocytes (LPH), the ratio PLT/LPH and PLT/
NPF, as well as the ratio of the percentage of NPH/LPH
were determined. Results: the activation of granulocyte
germ of hematopoiesis in patients with neuroectodermal (gliomas) and mesenchymal (meningioma) tumors
was established. The absolute content of NPF increased
in parallel with an increase in the degree of anaplasia
with gliomas. The ratio of PLT/LPH was significantly
higher in patients with glioblastomas compared with the
same index in patients with fibrillar protoplasmic astrocytomas. The percentage of LPH in patients with pituitary adenomas practically did not differ from the comparison group. In parallel with an increase in the degree of anaplasia of glioma, the values of PLT/LPH and
NPH/LPH significantly increased in the PLT/NPH index. Conclusions: the content in peripheral blood of patients with brain tumors of congenital (NPH) cells and
adaptive (LPH) immunity depends on the histogenesis
and degree of malignancy of the tumor. In malignant
References
Subeikshanan V, Dutt A, Basu, et al. A prospective comparative clinical study of peripheral blood counts and indices in patients
with primary braine tumors. J Postgrad Med 2016; 62 (2): 86–90.
Zavarzin AA. Ocherki evolucionnoiy histologii krovi I soedinitelnoy tkani 1945. M: Medgiz. 155 p. (in Russian).
Li Z, Ya Yang F, Dunn S, et al. Platelets as immune mediators: Their role host defense responses and sepsis. Tromb Res
; 127 (3): 184–8.
Menter DG, Tucker SC, Kopez S, et al. Platelets and cancer: a casual or causual relationship: revisited. Cancer Metastasis
Rev 2014; 33 (1): 231–69.
Connoly G, Khorana AA, Kuderer NM, et al. Leukocytosis,
trombosis and early mortality in cancer patients initiating chemotherapy. Tromb Res 2010; 126 (2): 113–8.
Mitrungno A, Tormoen GW, Kuhn P, McCarty OJT. The
protrombotic activity of cancer cells in the circulation. Blood Rev
; 30 (1): 11–9.
Jang P, Ren Ya, Lan Y, et al. Phagocytosis of platelets enchances endothelial cell survival under serum deprivation. Exp Biol
Med (Maywood) 2015; 240 (7): 876–83.
Weber M, Zuka M, Lorger M, et al. Activated tumor cell
integrin αvβ3 соoperates with platelets to promote extravasational
metastasis from the blood stream. Tromb Res 2016; 140 (1): 27–36.
Pucci F, Riokelt S, Newton AP, et al. PF4 promotes platelet
production and lung cancer growth. Cell Rep 2016; 17 (7): 1764–72.
Hisada Y, Geddings JE, Mackman N. Venous thrombosis
and cancer: from mouse models to clinical trials. J Thromb Haemost 2015; 13 (18): 1372–82.
Kim J, Bae J-S. Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediators Inflamm 2016,
: 6058147. doi:10 1155/2016/6058147.
Morrell CN, Aggrey AA, Chapman LM, Modjeski KL.
Emerging roles for platelets as immune and inflammatory cells.
Blood 2014; 123 (18): 2759–67.
Han S, Liu Y, Li Q, et al. Pre-treatment neutrophil to lymphocyte ratio is associated with neutrophil and T cell infiltration
and predicts clinical outcome in in patients with glioblastoma.
Cancer 2015; 15: 617.
Anezova R, Ryskeldiev N, Doskaliev A, et al. Assosiation of
preoperative levels of selected blood inflammatory markers with
prognosis in gliomas. Onco Targets Ther 2016; (9): 611–7.
Bambury RM, Teo MY, Power DC, et al. The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multoforme. J Neurooncol 2013; 114: 149–54.
Lisyanyi NI, Gnedkova IA, Kot LA, et al. The blood peripheral content of the cells of innate and adaptive immunity in
patients with brain tumors of various histogenesis. Ukr Neurosurgical J 2017; (4): 38–41 (in Russian).
Gieden PR, Schulte BM, Kers-Rebel ED, et al. Elevated
levels of polymorphoneclear myeloid-derived suppressor cells in
patients with glioblastoma highly express S100 A8/9 and arginase
a suppress T cell function. Neuro Oncol 2016; 18 (9): 1253–64.
Gieryng A, Kaminska B. Myeloid-derived suppressor
cells in gliomas. Contemp Oncol (Pozn) 2016; 20 (5): 345–51.
doi.:10.45114/wo.2016.64592.
Hung Y, Rajappa P, Hu W, et al. A proangiogenic signaling axis in myeloid cells promotes malignant progression of glioma. J Clin Invest 2017; 12715/1826–1838. doi. 10.1172/jc186443.
Kyznik BI, Vasiliev NV, Cibikov NI. Immunogenez, hemostaz i nespecificheskaya rezistentnost organizma. M: Medicina, 1989. 320 p. (in Russian).
